Health & bio
Pasithea PAS-004 earns Fast Track status for NF1-associated plexiform neurofibromatosis
Pasithea Therapeutics said April 1 its next-gen macrocyclic MEK inhibitor PAS-004 earned FDA Fast Track designation for NF1-associated plexiform neurofibromatosis.
Primary sources · 1